ESPR Q1 2021 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q1 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$8M+333.6% YoY

Gross Profit

$6M77.6% margin

Operating Income

-$83M-1038.2% margin

Net Income

-$91M-1139.8% margin

EPS (Diluted)

$-3.50

QoQ Revenue Growth

-17.2%

Cash Flow

Operating Cash Flow

-$89M

Free Cash Flow

-$89M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$279M

Total Liabilities

$548M

Stockholders' Equity

-$269M

Cash & Equivalents

$218M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$2M	+333.6%
Gross Profit	$6M	$2M	+242.4%
Operating Income	-$83M	-$74M	-11.3%
Net Income	-$91M	-$78M	-16.2%

Revenue Segments

Collaboration Revenue

$2M50%

Product Sales Bulk Tablets Nilemdo And Nustendi

$2M50%